Florida-based Valensa International has signed licensing agreements for its astaxanthin

Posted On: October 13, 2009

Valensa’s deal comes at the same time it has joined with krill omega-3 specialist, Neptune Technologies and Bioressources to develop astaxanthin-omega-3 combinations.

Valensa says its patent-protected process (University of Illinois; US 5,527,533) can be used by New York-based FutureBiotics; North Dakota-based Swanson Health Products and Arizona-based Life Extension Vitamins in eye health supplements.

The patent is relevant for light-induced retinal damage, age-related macular degeneration, photoreceptor cell retinal damage and damage to neurons of inner retinal layers and produces an ingredient with a four-year shelf life, Valensa said.

More info